Citius Pharmaceuticals, Inc.
CTXR
$1.37
$0.010.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.37% | -5.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.96% | 12.16% | |||
| Operating Income | 21.96% | -12.16% | |||
| Income Before Tax | 20.52% | -12.28% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | 20.05% | -11.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -30.42% | 15.98% | |||
| Net Income | 19.48% | -11.76% | |||
| EBIT | 21.96% | -12.16% | |||
| EBITDA | 21.96% | -12.16% | |||
| EPS Basic | 37.22% | 2.42% | |||
| Normalized Basic EPS | 37.32% | 2.26% | |||
| EPS Diluted | 37.22% | 2.42% | |||
| Normalized Diluted EPS | 37.32% | 2.26% | |||
| Average Basic Shares Outstanding | 28.27% | 14.53% | |||
| Average Diluted Shares Outstanding | 28.27% | 14.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||